Jie Cheng, Guanghua Chen, Hui Lv, Liangjing Xu, Huiwen Liu, Tianping Chen, Lijun Qu, Jian Wang, Lemei Cheng, Shaoyan Hu, Yi Wang
BioMed research international 2021To explore the immune cell therapy for T cell lymphoma, we developed CD4-specific chimeric antigen receptor- (CAR-) engineered T cells (CD4CART), and the cytotoxic effects of CD4CART cells were determined in vitro and in vivo. CD4CART cells were obtained by transduction of lentiviral vector encoding a single-chain antibody fragment (scFv) specific for CD4 antigen, costimulatory factor CD28 fragment, and intracellular signal transduction domain of CD3 fragments. Control T cells were obtained by transduction of reporter lentiviral vector. The cytotoxicity, tumor growth, and survival rate of mice with T cell lymphoma were analyzed after adoptive T cell transfer in vivo. CD4CART cells had potent cytotoxic activity against CD4+ T1301 tumor T cells in a concentration-dependent manner. In addition, adoptive CD4CART cell transfer significantly suppressed tumor growth and improved animal survival with T cell lymphoma, compared to the mice who received control T cells and PBS. CD4CART cells have potent cytotoxic effects on T cell lymphoma. The study provided an experimental basis for CD4CART-mediated therapy of T cell lymphoma. Copyright © 2021 Jie Cheng et al.
Jie Cheng, Guanghua Chen, Hui Lv, Liangjing Xu, Huiwen Liu, Tianping Chen, Lijun Qu, Jian Wang, Lemei Cheng, Shaoyan Hu, Yi Wang. CD4-Targeted T Cells Rapidly Induce Remissions in Mice with T Cell Lymphoma. BioMed research international. 2021;2021:6614784
PMID: 33855074
View Full Text